Krystal Biotech's Chief Executive Officer, Krish Krishnan, will be presenting at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 in Miami. A webcast of the presentation will be available here: https://krys.bio/t8s beginning at 10:40 am ET on June 11 and will be posted on the Investors section of the Company’s website: https://krys.bio/ub0
Krystal Biotech, Inc.’s Post
More Relevant Posts
-
Experienced professional specializing in Deal Strategy and Execution. DEI and Mental Health Advocate
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
To view or add a comment, sign in
-
Director, Human Capital Advisory, with a focus on State and Local Government, Industrial Manufacturing, Consumer & Retail as well as Healthcare and Life Sciences at KPMG
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:
How biotech companies are standing out during JPM Week
kpmg.voicestorm.com
To view or add a comment, sign in
-
International Tax Director - PwC | Committed to distilling complexity into simple, practical solutions for international businesses | Focussed on Pharma | IP & Operating Model Specialist
Our latest M&A trends reveal how M&A will continue to be a critical tool to unlock value and innovation across Health, Pharma and Life Sciences. This was echoed in our latest UK #ValueCreation roundtable with @Alan Milburn and senior industry dealmakers. From funding to integration, we discussed the role and importance of transactions to create sustained value. Check out our latest #PwCDeals #IndustryTrends to find out more https://pwc.to/3VM4qMG
To view or add a comment, sign in
-
In advance of our 2023 Global Healthcare Conference in London, we sat down with the leaders of our Healthcare Investment Banking and Healthcare Equity Research teams to hear what they had to say about the opportunities and challenges they see in the market. They discuss everything from their cautious optimism about the markets to funding challenges to a bounce back for M&A, and even weigh-in on the emergence and outlook of weight-loss drugs. See some of what they had to say below and access their full interviews, plus the results of the 6th edition of the Jefferies Healthcare Temperature Check, here: https://lnkd.in/gvNzxQEW These, and many other topics, will be on the agenda during our three-day Healthcare Conference in Europe. We're expecting a record attendance of over 3,000 participants representing nearly 700 healthcare corporates, private equity and venture capital firms, institutional investors, and other leaders from the healthcare sector. #JefferiesHealthcare
To view or add a comment, sign in
-
Last week our CEO Greg Smith took part in a panel moderated by Bloomberg's Ashleigh Furlong alongside several other industry peers and experts (Richard Bungay, Linden Thomson, CFA, Clare Terlouw and Bernard Cooney) at the London Stock Exchange’s Future of Healthcare Investment Forum entitled ‘Financing Healthcare – UK, US, Private and Public’. This marked a great opportunity to discuss the recent challenges and future opportunities in the healthcare sector, particularly long-term capital interest in science and technology scale up investment. IP Group plc is the UK’s most active investor in science and innovation companies and are behind some of most exciting breakthroughs of the last 20 years. We are strategically positioned to capitalise on the rapid advancements in pharmaceuticals and healthcare delivery, with over ten companies now in clinical studies and expecting key data by the end of 2025. We believe the UK can be a science superpower - if we get the conditions right. #LifeSciences #Healthcare
To view or add a comment, sign in
21,996 followers